XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Information

Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

​

2025

2024

​

2025

2024

Program expenses related to clinical-stage product candidates1

​

$

(4,799,800)

​

$

(1,078,604)

​

$

(11,595,094)

​

$

(8,858,608)

Program expenses related to preclinical and discovery programs

​

​

(119,507)

​

​

(200,759)

​

​

(333,746)

​

​

(661,572)

Program expenses related to clinical manufacturing candidates

​

​

(679,713)

​

​

(862,378)

​

​

(2,196,348)

​

​

(3,487,187)

Personnel-related expenses (including stock-based compensation)

​

​

(1,218,491)

​

​

(1,125,522)

​

​

(4,113,009)

​

​

(4,666,720)

General and administrative professional and consultant fees

​

​

(468,749)

​

​

(491,027)

​

​

(1,206,263)

​

​

(1,250,575)

Other segment items2

​

​

(148,715)

​

​

(629,321)

​

​

(544,649)

​

​

(1,035,394)

Interest income

​

​

152,317

​

​

135,430

​

​

531,324

​

​

205,576

Other non-cash income (expense) items3

​

​

20,000

​

​

(8,386,176)

​

​

438,000

​

​

1,028,764

Net Loss

​

$

(7,262,658)

​

$

(12,638,357)

​

$

(19,019,785)

​

$

(18,725,716)

​

¹ For the three months ended September 30, 2025 $4.1 million of this expense relates to our AD 6 month trial and $0.7 million of this expense relates to our PD Open Label Extension study. The remaining $0.1 million reflects clinical costs not specifically associated with either study.

² Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.

³ Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration